BHVN - Biohaven: Promising Pipeline With Troriluzole Taldefgrobep Alfa And BHV-7000 Leading The Charge

2024-05-18 03:10:13 ET

Summary

• Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field.
• BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder.
• Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology.
• Upcoming catalysts include FDA approval decisions and clinical trial results, which could significantly impact BHVN's stock performance.
• Despite the short cash runway, BHVN is a 'buy' due to its promising drug candidates and upcoming catalysts.

...

For further details see: